Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance and biotransformation of WPV01 in healthy Chinese males
NCT07080658Phase 1Completed
- Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iscartrelvir in coronavirus disease 2019 (COVID-19), sponsored by Westlake Pharmaceuticals (Hangzhou) Co., Ltd. Primary endpoints: Total recovery and cumulative recovery of total WPV01-related radioactive material in excreta at 168 hours, Total radioactivity of WPV01-related substances in human plasma at 168 hours and 2 more. Started Jul 2023; status: completed.
02
Drugs
iscartrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07080658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07080658.